The dropout rate in the study remains unexpectedly low. Topline results are expected at the end of Q1 2023. The study compound, Sepranolone, is an endogenous neurosteroid, an entirely new treatment modality for Tourette. It has demonstrated a strong safety prolife in multiple previous clinical studies, and reduced tics without inducing any motor side effects in previous preclinical studies.
Enrollment of adult patients started at the
Low dropout rate maintained
As reported in
Peter Nordkild, CEO: 'Our work with the highly experienced teams at Bispebjerg and Herlev University Hospitals is progressing very positively. I'd like to thank the two teams for their tremendous expertise in ensuring a smooth study with highly motivated patients. We look forward to sharing our topline results.'
About Tourette: the unmet need
The unmet need for a safe and effective treatment is significant. A new 2022 study by the
The majority of Tourette cases occur in children between 4 - 12 year's old, for some patients it persists into adulthood. Current treatments like haloperidol (Haldol) can involve extremely severe side effects. 44% of parents feel that current Tourette treatments fail to adequately control their child's symptoms, and 29% of children have tried five or more different medications (2).
Sepranolone: a new approach to Tourette
If full clinical development and regulatory approval is successful, Sepranolone will be the first endogenous, neuroendocrinological compound used to treat Tourette - representing an entirely new treatment modality with no serious side effects. Sepranolone is highly selective and has been designed to target and modulate the effects of allopregnanolone - a powerful neurosteroid in the exacerbation of tics - with no off-target Central Nervous System side effects.
Allopregnanolone is also implicated in a wide range of other stress and compulsion disorders. Sepranolone is
Contact:
Peter Nordkild
Tel: +45 25 47 16 46
Email: peter.nordkild@asarinapharma.com
ABOUT
We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.
(C) 2022 Electronic News Publishing, source